Vor Bio highlights telitacicept BAFF/APRIL inhibitor as lead program in B cell-driven autoimmune diseases

Vor Biopharma outlined its BAFF/APRIL inhibitor telitacicept strategy to treat B cell-driven autoimmune diseases.

• Global Phase 3 enrollment has been completed in generalized myasthenia gravis; topline data are expected in 1H27.
• Ocular myasthenia gravis Phase 3 first patient dosed is expected in 1H27; primary Sjögren's disease Phase 3 enrollment is ongoing.
• The company reported a cash position of about $515 million, with runway projected into early 2029.
• In China, a Phase 3 gMG study showed a 4.8-point MG-ADL separation versus placebo at week 24 and a 6.4-point QMG separation.